Demand for weight loss medication overwhelms key health and production players

Pharma giant Novo Nordisk and health insurance association Sygeforsikringen Danmark both impacted by immense popularity of Wegovy

Earlier this year, health insurance company Sygeforsikringen Danmark said it was reconsidering its stance on reimbursing customers who take out a prescription for Novo Nordisk drug Wegovy, an effective but expensive weight loss medicine launched last year.

Well, consider the issue reconsidered.

Sygeforsikringen Danmark has announced that it will halt subsidies for Wegovy for its 2.7 million members.

“Unfortunately, since the turn of the year, the increase in subsidies for weight loss medicine has been to such an extent that we have had to look more closely at how we as an association can best protect our members in a broader perspective”, said Allan Luplau, CEO of Sygeforsikringen Danmark.

Sygeforsikringen Danmark is a member-owned association who receive subsidies for medication, glasses, contact lenses, physiotherapy, vaccinations and more.

“We have decided that from January 1, 2024, the subsidy for weight loss medicine will be removed – regardless of the brand – unless the member has been granted a single subsidy by the Danish Medicines Agency via the doctor,” said Luplau.

READ ALSO: Market movers: Danish firm soars past global giants 

Novo Nordisk can’t keep up
Wegovy producer Novo Nordisk is also feeling the pressure, announcing that it cannot meet the demand for Wegovy.

Novo Nordisk’s first quarter results that were posted today showed that earnings had skyrocketed to 19.8 billion kroner – a growth of 39 percent compared to the same period last year. The rise was partially driven by Wegovy.

But, despite that success, Denmark’s most valuable company has been forced to reduce access to starting doses of Wegovy in the US due to the immense demand.

“We basically see linear growth continuing. And I don’t think it comes as a surprise that we can’t cover a demand that just continues to grow,” Lars Fruergaard Jørgensen, the head of Novo Nordisk, said according to MarketWire.

According to some figures, over 100,000 Wegovy prescriptions are taken out every week in the US.

And in just a few months, Wegovy has become the dominant drug for weight loss in Denmark.





  • How internationals can benefit from joining trade unions

    How internationals can benefit from joining trade unions

    Being part of a trade union is a long-established norm for Danes. But many internationals do not join unions – instead enduring workers’ rights violations. Find out how joining a union could benefit you, and how to go about it.

  • Internationals in Denmark rarely join a trade union

    Internationals in Denmark rarely join a trade union

    Internationals are overrepresented in the lowest-paid fields of agriculture, transport, cleaning, hotels and restaurants, and construction – industries that classically lack collective agreements. A new analysis from the Workers’ Union’s Business Council suggests that internationals rarely join trade unions – but if they did, it would generate better industry standards.

  • Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    The numbers are especially striking amongst the 3,477 business and economics students polled, of whom 31 percent elected Novo Nordisk as their favorite, compared with 20 percent last year.